Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models

Thyroid

Volumn 17, Issue 4, 2007, Pages 289-301

  Lee, Jia Jing ^a   Foukakis, Theodoros ^a   Hashemi, Jamileh ^a   Grimelius, Lars ^b   Heldin, Nils Erik ^b   Wallin, Göran ^a   Rudduck, Christina ^a   Lui, Weng Onn ^a   Höög, Anders ^a   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 20Q; CHROMOSOME 3P; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; KARYOTYPING; MALE; PATHOGENESIS; PRIORITY JOURNAL; THYROID CANCER; THYROID CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; SPECTRAL KARYOTYPING; THYROID NEOPLASMS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 34248632548     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0246     Document Type: Article

References (40)

1. Giuffrida D, Gharib H 2000 Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 11:1083-1089.
2. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15:319-327.
3. Wallin G, Backdahl M, Tallroth-Ekman E, Lundell G, Auer G, Lowhagen T 1989 Co-existent anaplastic and well differentiated thyroid carcinomas: a nuclear DNA study. Eur J Surg Oncol 15:43-48.
4. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306.
5. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
6. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115:94-101.
7. Frisk T, Foukakis T, Dwight T, Lundberg J, Hoog A, Wallin G, Eng C, Zedenius J, Larsson C 2002 Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 35:74-80.
8. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C 2000 Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700.
9. Heldin NE, Cvejic D, Smeds S, Westermark B 1991 Co-expression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 129:2187-2193.
10. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653.
11. Dahlman T, Lammerts E, Bergstrom D, Franzen A, Westermark K, Heldin NE, Rubin K 2002 Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicity. Int J Cancer 98:186-192.
12. Aust G, Hofmann A, Laue S, Rost A, Kohler T, Scherbaum WA 1997 Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein. Thyroid 7:713-724.
13. Carlsson J, Nilsson K, Westermark B, Ponten J, Sundstrom C, Larsson E, Bergh J, Pahlman S, Busch C, Collins VP 1983 Formation and growth of multicellular spheroids of human origin. Int J Cancer 31:523-533.
14. Mark J, Ekedahl C, Dahlenfors R, Westermark B 1987 Cytogenetical observations in five human anaplastic thyroid carcinomas. Hereditas 107:163-174.
15. Dahlman T, Lammerts E, Wik M, Bergstrom D, Grimelius L, Westermark K, Rubin K, Heldin NE 2000 Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis. J Pathol 191:376-386.
16. Ain KB, Taylor KD 1994 Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1097-1102.
17. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A Transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:31365-31368.
18. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T 1996 Multicolor spectral karyotyping of human chromosomes. Science 273:494-497.
19. Mitelman F, (ed). 1995 An International System for Human Cytogenetic Nomenclature. Karger, Basel.
20. Thelander EF, Walsh SH, Thorselius M, Laurell A, Landgren O, Larsson C, Rosenquist R, Lagercrantz S 2005 Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod Pathol 18:331-339.
21. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
22. Foukakis T, Au AY, Wallin G, Geli J, Forsberg L, Clifton-Bligh R, Robinson BG, Lui WO, Zedenius J, Larsson C 2006 The RAS effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J Clin Endocrinol Metab 91:1143-1149.
23. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, Fusco A 2005 UBCH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 93:464-471.
24. Kammori M, Onoda N, Nakamura K, Izumiyama N, Ogisawa K, Kurabayashi R, Ogawa T, Kaminishi M, Poon SS, Takubo K 2006 Specific subtelomere loss on chromosome der(11)t(3;11)(q23;q23)x2 in anaplastic thyroid cancer cell line OCUT-1. Int J Mol Med 18:9-16.
25. Belge G, Roque L, Soares J, Bruckmann S, Thode B, Fonseca E, Clode A, Bartnitzke S, Castedo S, Bullerdiek J 1998 Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between bytogenetic findings and histology. Cancer Genet Cytogenet 101:42-48.
26. Lui WO, Kytola S, Anfalk L, Larsson C, Farnebo LO 2000 Balanced translocation (3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma? Cancer Genet Cytogenet 119:109-112.
27. Foukakis T, Thoppe SR, Lagercrantz S, Dwight T, Weng WH, Svensson A, Hoog A, Zedenius J, Wallin G, Lui WO, Larsson C 2005 Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. Int J Oncol 26:141-149.
28. Ji L, Minna JD, Roth JA 2005 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 1:79-92.
29. Rodrigues-Serpa A, Catarino A, Soares J 2003 Loss of heterozygosity in follicular and papillary thyroid carcinomas. Cancer Genet Cytogenet 141:26-31.
30. Bol S, Belge G, Thode B, Bonk U, Bartnitzke S, Bullerdiek J 2001 Cytogenetic tetraclonality in a rare spindle cell variant of an anaplastic carcinoma of the thyroid. Cancer Genet Cytogenet 114:1-6.
31. Miura D, Wada N, Chin K, Magrane GG, Wong M, Duh QY, Clark OH 2003 Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid 13:283-290.
32. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H 1999 DNA copy number changes in thyroid carcinoma. Am J Pathol 154:1539-1547.
33. Wilkens L, Benten D, Tchinda J, Brabant G, Pötter E, Dralle H, von Wasielewski R 2000 Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridization and comparative genomic hybridization. Virchows Arch 436:312-318.
34. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B 2002 Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161:1549-1556.
35. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J 2004 Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90:492-496.
36. Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SGM, van Diest PJ, Albertson DG, Meijer GA 2003 Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol 200:320-326.
37. Hodgson JG, Chin K, Collins C, Gray JW 2003 Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res and Treat 78:337-345.
38. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J 2006 A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26:1178-1187.
39. Galera-Davidson H, Bibbo M, Dytch HE, Gonzalez-Campora R, Fernandez A, Wied GL 1987 Nuclear DNA in anaplastic thyroid carcinoma with a differentiated component. Histopathology 11:715-722.
40. Mitelman F, Johansson B, Mertens F (eds.) 2006 Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman